Alumis, Kaken Pharmaceutical Enter Collaboration, Licensing Deal for Dermatology Drug

MT Newswires Live
03-25

Alumis (ALMS) and Kaken Pharmaceutical have struck a collaboration and licensing agreement to develop, manufacture and commercialize ESK-001 for dermatology indications in Japan, with an option to expand the license to include rheumatological and gastrointestinal diseases, the companies said Tuesday.

Under the terms of the agreement, Alumis will receive $40 million in upfront and near-term co-development payments this year and next year, with the potential to earn up to approximately $140 million in additional milestone payments, the companies said.

Alumis is also eligible to receive tiered royalties ranging from the low double-digits into the twenties on total Japanese net sales of ESK-001, the companies said.

Kaken will be responsible for the clinical development, regulatory approvals and commercialization of ESK-001 in Japan and contribute toward global development costs of the drug, the companies said.

The drug is currently being evaluated in a phase 3 clinical trial for patients with moderate-to-severe plaque psoriasis, the companies said.

Shares of Alumis gained more than 14% in premarket activity.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10